nach oben

Neurotoxicity Research

Erschienen in:

01.10.2013 | Short Report/Rapid Communication

Peripherally Applied Synthetic Peptide isoAsp7-Aβ(1-42) Triggers Cerebral β-Amyloidosis

verfasst von: S. A. Kozin, I. B. Cheglakov, A. A. Ovsepyan, G. B. Telegin, P. O. Tsvetkov, A. V. Lisitsa, A. A. Makarov

Erschienen in: Neurotoxicity Research | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Intracerebral and intraperitoneal inoculation with β-amyloid-rich brain extracts originating from patients with Alzheimer’s disease as well as intracerebral injection of aggregates composed of synthetic Aβ can induce cerebral β-amyloidosis, and associated cognitive dysfunctions in susceptible animal hosts. We have found that repetitive intravenous administration of 100 μg of synthetic peptide corresponding to isoAsp7-containing Aβ(1-42), an abundant age-dependent Aβ isoform present both in the pathological brain and in synthetic Aβ preparations, robustly accelerates formation of classic dense-core congophilic amyloid plaques in the brain of β-amyloid precursor protein transgenic mice. Our findings indicate this peptide as an inductive agent of cerebral β-amyloidosis in vivo.

Archer T, Kostrzewa R, Beninger R, Palomo T (2011) Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions. Neurotox Res 19(2):211–234. doi:10.1007/s12640-010-9190-2 PubMedCrossRef

Bachurin S, Shelkovnikova T, Ustyugov A, Peters O, Khritankova I, Afanasieva M, Tarasova T, Alentov I, Buchman V, Ninkina N (2012) Dimebon slows progression of proteinopathy in γ-Synuclein transgenic mice. Neurotox Res 22(1):33–42. doi:10.1007/s12640-011-9299-y PubMedCrossRef

Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ (1993) Evidence for the experimental transmission of cerebral beta-amyloidosis to primates. Int J Exp Pathol 74(5):441–454PubMed

Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19(4):939–945PubMedCrossRef

Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, Roth K, Aguzzi A, Staufenbiel M, Walker LC, Jucker M (2009) Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A 106(31):12926–12931. doi:10.1073/pnas.0903200106 PubMedCrossRef

Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M (2010) Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330(6006):980–982. doi:10.1126/science.1194516 PubMedCrossRef

Franklin K, Paxinos G (2008) The mouse brain in stereotaxic coordinates. Academic Press, New York

Fukuda H, Shimizu T, Nakajima M, Mori H, Shirasawa T (1999) Synthesis, aggregation, and neurotoxicity of the Alzheimer’s Aß1-42 amyloid peptide and its isoaspartyl isomers. Bioorg Med Chem Lett 9(7):953–956. doi:10.1016/s0960-894x(99)00121-3 PubMedCrossRef

Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME (2010) Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol 68(2):220–230. doi:10.1002/ana.22052 PubMed

Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP (2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24(3):516–524PubMedCrossRef

Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101–112. doi:10.1038/nrm2101 PubMedCrossRef

Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356. doi:10.1126/science.1072994297/5580/353 PubMedCrossRef

Holtzman DM, Morris JC, Goate AM (2011) Alzheimer’s disease: the challenge of the second century. Sci Transl Med 3(77):77sr1. doi:10.1126/scitranslmed.3002369 PubMedCrossRef

Hosoda R, Saido TC, Otvos L Jr, Arai T, Mann DM, Lee VM, Trojanowski JQ, Iwatsubo T (1998) Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J Neuropathol Exp Neurol 57(11):1089–1095PubMedCrossRef

Indeykina MI, Popov IA, Kozin SA, Kononikhin AS, Kharybin ON, Tsvetkov PO, Makarov AA, Nikolaev EN (2011) Capabilities of MS for analytical quantitative determination of the ratio of alpha- and betaAsp7 isoforms of the amyloid-beta peptide in binary mixtures. Anal Chem 83(8):3205–3210. doi:10.1021/ac103213j PubMedCrossRef

Jucker M, Walker LC (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70(4):532–540. doi:10.1002/ana.22615 PubMedCrossRef

Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC (2000) Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. J Neurosci 20(10):3606–3611PubMed

Kumar S, Rezaei-Ghaleh N, Terwel D, Thal DR, Richard M, Hoch M, Mc Donald JM, Wullner U, Glebov K, Heneka MT, Walsh DM, Zweckstetter M, Walter J (2011) Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer’s disease. EMBO J 30(11):2255–2265PubMedCrossRef

Kumar S, Singh S, Hinze D, Josten M, Sahl HG, Siepmann M, Walter J (2012) Phosphorylation of amyloid-beta peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. J Biol Chem 287(11):8641–8651PubMedCrossRef

Kuo Y-M, Emmerling MR, Woods AS, Cotter RJ, Roher AE (1997) Isolation, chemical characterization, and quantitation of Aβ 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun 237(1):188–191. doi:10.1006/bbrc.1997.7083 PubMedCrossRef

Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M (2011) Soluble Abeta seeds are potent inducers of cerebral beta-amyloid deposition. J Neurosci 31(41):14488–14495. doi:10.1523/JNEUROSCI.3088-11.2011 PubMedCrossRef

Masters CL, Selkoe DJ (2012) Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med 2(6):a006262. doi:10.1101/cshperspect.a006262 PubMedCrossRef

Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313(5794):1781–1784. doi:10.1126/science.1131864 PubMedCrossRef

Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C (2012) De novo induction of amyloid-beta deposition in vivo. Mol Psychiatry 17(12):1347–1353. doi:10.1038/mp.2011.120 PubMedCrossRef

Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL (2009) γ-Synucleinopathy: neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet 18(10):1779–1794. doi:10.1093/hmg/ddp090 PubMedCrossRef

Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Ronicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 485(7400):651–655. doi:10.1038/nature11060 PubMedCrossRef

Peters OM, Connor-Robson N, Sokolov VB, Aksinenko AY, Kukharsky MS, Bachurin SO, Ninkina N, Buchman VL (2013a) Chronic administration of dimebon ameliorates pathology in TauP301S transgenic mice. J Alzheimers Dis 33(4):1041–1049. doi:10.3233/JAD-2012-121732 PubMed

Peters OM, Shelkovnikova T, Tarasova T, Springe S, Kukharsky MS, Smith GA, Brooks S, Kozin SA, Kotelevtsev Y, Bachurin SO, Ninkina N, Buchman VL (2013b) Chronic administration of dimebon does not ameliorate amyloid-β pathology in 5xFAD transgenic mice. J Alzheimers Dis. doi:10.3233/JAD-130071

Prusiner SB (2012) A unifying role for prions in neurodegenerative diseases. Science 336(6088):1511–1513. doi:10.1126/science.1222951 PubMedCrossRef

Ridley RM, Baker HF, Windle CP, Cummings RM (2006) Very long term studies of the seeding of beta-amyloidosis in primates. J Neural Transm 113(9):1243–1251. doi:10.1007/s00702-005-0385-2 PubMedCrossRef

Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zurcher-Neely HA, Heinrikson RL, Ball MJ et al (1993) Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer’s disease. J Biol Chem 268(5):3072–3083PubMed

Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo Y-M, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimers Dement 5(1):18–29. doi:10.1016/j.jalz.2008.10.004 PubMedCrossRef

Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, Lah JJ, LeVine H 3rd, Jucker M, Walker LC (2012) Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. J Neurochem 120(5):660–666. doi:10.1111/j.1471-4159.2011.07551.x PubMedCrossRef

Shimizu T, Watanabe A, Ogawara M, Mori H, Shirasawa T (2000) Isoaspartate formation and neurodegeneration in Alzheimer’s disease. Arch Biochem Biophys 381(2):225–234PubMedCrossRef

Shimizu T, Fukuda H, Murayama S, Izumiyama N, Shirasawa T (2002) Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer’s disease. J Neurosci Res 70(3):451–461. doi:10.1002/jnr.10350 PubMedCrossRef

Shimizu T, Matsuoka Y, Shirasawa T (2005) Biological significance of isoaspartate and its repair system. Biol Pharm Bull 28(9):1590–1596PubMedCrossRef

Stöhr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, Prusiner SB, Giles K (2012) Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions. Proc Natl Acad Sci 109(27):11025–11030. doi:10.1073/pnas.1206555109 PubMedCrossRef

Toropygin IY, Kugaevskaya EV, Mirgorodskaya OA, Elisseeva YE, Kozmin YP, Popov IA, Nikolaev EN, Makarov AA, Kozin SA (2008) The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer’s Abeta-(1–16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 22(2):231–239. doi:10.1002/rcm.3357 PubMedCrossRef

Tsvetkov PO, Popov IA, Nikolaev EN, Archakov AI, Makarov AA, Kozin SA (2008) Isomerization of the Asp7 residue results in zinc-induced oligomerization of Alzheimer’s disease amyloid beta(1–16) peptide. ChemBioChem 9(10):1564–1567. doi:10.1002/cbic.200700784 PubMedCrossRef

Tsvetkov FO, Makarov AA, Archakov AI, Kozin SA (2009) Effect of isomerization of aspartate-7 on the binding of copper (II) ion by the β-amyloid peptide. Biophysics 54(2):131–134. doi:10.1134/s0006350909020018 CrossRef

Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE, Lipinski WJ (2002) Exogenous induction of cerebral β-amyloidosis in βAPP-transgenic mice. Peptides 23(7):1241–1247PubMedCrossRef

Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ, Prusiner SB (2011) Bioluminescence imaging of Aβ deposition in bigenic mouse models of Alzheimer’s disease. Proc Natl Acad Sci 108(6):2528–2533. doi:10.1073/pnas.1019034108 PubMedCrossRef

Yardeni T, Eckhaus M, Morris HD, Huizing M, Hoogstraten-Miller S (2011) Retro-orbital injections in mice. Lab Anim (NY) 40(5):155–160. doi:10.1038/laban0511-155 CrossRef

Zirah S, Kozin SA, Mazur AK, Blond A, Cheminant M, Segalas-Milazzo I, Debey P, Rebuffat S (2006) Structural changes of region 1–16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J Biol Chem 281(4):2151–2161. doi:10.1074/jbc.M504454200 PubMedCrossRef

Titel: Peripherally Applied Synthetic Peptide isoAsp7-Aβ(1-42) Triggers Cerebral β-Amyloidosis
verfasst von: S. A. Kozin
I. B. Cheglakov
A. A. Ovsepyan
G. B. Telegin
P. O. Tsvetkov
A. V. Lisitsa
A. A. Makarov
Publikationsdatum: 01.10.2013
Verlag: Springer US
Erschienen in: Neurotoxicity Research / Ausgabe 3/2013
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-013-9399-y

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Neurotoxic Saboteurs: Straws that Break the Hippo’s (Hippocampus) Back Drive Cognitive Impairment and Alzheimer’s Disease

The Effect of Lipoic Acid on Cyanate Toxicity in Different Structures of the Rat Brain

Protective Effects of Memantine Against Methylmercury-Induced Glutamate Dyshomeostasis and Oxidative Stress in Rat Cerebral Cortex

The Effects of Cocaine on Different Redox Forms of Cysteine and Homocysteine, and on Labile, Reduced Sulfur in the Rat Plasma Following Active versus Passive Drug Injections

Salicylate Selectively Kills Cochlear Spiral Ganglion Neurons by Paradoxically Up-regulating Superoxide

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease